Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Atara Biotherapeutics (ATRA) Other financing activities (2022 - 2023)

Atara Biotherapeutics filings provide 2 years of Other financing activities readings, the most recent being -$13000.0 for Q2 2023.

On a quarterly basis, Other financing activities changed N/A to -$13000.0 in Q2 2023 year-over-year; TTM through Sep 2024 was -$13000.0, a 100.04% decrease, with the full-year FY2025 number at -$1000.0, up 85.71% from a year prior.
Other financing activities hit -$13000.0 in Q2 2023 for Atara Biotherapeutics, down from $30.8 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $30.8 million in Q4 2022 to a low of -$104000.0 in Q1 2022.